{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tiragolumab", "query": { "intervention": "Tiragolumab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 44, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tiragolumab&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T08:44:23.944Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05746481", "title": "Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Liza Villaruz, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2023-08-10", "completion_date": "2025-11-08", "has_results": true, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-09-02T08:44:23.944Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05746481" }, { "nct_id": "NCT05286801", "title": "Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Atypical Teratoid/Rhabdoid Tumor", "Epithelioid Sarcoma", "Kidney Medullary Carcinoma", "Malignant Solid Neoplasm", "Poorly Differentiated Chordoma", "Recurrent Atypical Teratoid/Rhabdoid Tumor", "Recurrent Chordoma", "Recurrent Epithelioid Sarcoma", "Recurrent Kidney Medullary Carcinoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Rhabdoid Tumor", "Refractory Atypical Teratoid/Rhabdoid Tumor", "Refractory Chordoma", "Refractory Epithelioid Sarcoma", "Refractory Kidney Medullary Carcinoma", "Refractory Malignant Solid Neoplasm", "Refractory Rhabdoid Tumor", "Rhabdoid Tumor" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Tiragolumab", "type": "BIOLOGICAL" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": null, "sex": "ALL", "summary": "12 Months and older" }, "enrollment_count": 86, "start_date": "2022-11-17", "completion_date": "2030-03-31", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-09-02T08:44:23.944Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05286801" }, { "nct_id": "NCT04929223", "title": "A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Inavolisib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" }, { "name": "SY-5609", "type": "DRUG" }, { "name": "Divarasib", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "FoundationOne®Liquid CDx", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 542, "start_date": "2021-10-22", "completion_date": "2030-08-31", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-09-02T08:44:23.944Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04929223" }, { "nct_id": "NCT04665843", "title": "A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 123, "start_date": "2021-03-02", "completion_date": "2025-08-27", "has_results": true, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-09-02T08:44:23.944Z", "location_count": 7, "location_summary": "La Jolla, California • Los Angeles, California • Tallahassee, Florida + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tallahassee", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04665843" }, { "nct_id": "NCT03784326", "title": "Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage II Esophageal Adenocarcinoma AJCC v8", "Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage II Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Conventional Surgery", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2019-02-19", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-09-02T08:44:23.944Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03784326" }, { "nct_id": "NCT04543617", "title": "A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Esophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Tiragolumab Matching Placebo", "type": "DRUG" }, { "name": "Atezolizumab Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 760, "start_date": "2020-09-28", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-09-02T08:44:23.944Z", "location_count": 3, "location_summary": "Fort Myers, Florida • Wichita, Kansas • Williamsville, New York", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Williamsville", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04543617" }, { "nct_id": "NCT04256421", "title": "A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 490, "start_date": "2020-02-04", "completion_date": "2025-07-31", "has_results": true, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-09-02T08:44:23.944Z", "location_count": 18, "location_summary": "Lone Tree, Colorado • Washington D.C., District of Columbia • Fort Myers, Florida + 15 more", "locations": [ { "city": "Lone Tree", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04256421" }, { "nct_id": "NCT05681039", "title": "Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma", "Oral Cavity Squamous Cell Carcinoma" ], "interventions": [ { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Standard of Care", "type": "BEHAVIORAL" }, { "name": "Questionnaires", "type": "BEHAVIORAL" }, { "name": "Cisplatin", "type": "RADIATION" }, { "name": "Carboplatin", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "BEHAVIORAL", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2023-06-02", "completion_date": "2026-11-01", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-09-02T08:44:23.944Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05681039" }, { "nct_id": "NCT05315713", "title": "An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin Lymphoma, Follicular Lymphoma" ], "interventions": [ { "name": "Mosunetuzumab SC", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2022-05-10", "completion_date": "2023-07-19", "has_results": true, "last_update_posted_date": "2024-10-04", "last_synced_at": "2026-09-02T08:44:23.944Z", "location_count": 3, "location_summary": "Los Angeles, California • Ann Arbor, Michigan • Providence, Rhode Island", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT05315713" }, { "nct_id": "NCT06754501", "title": "A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2025-04-11", "completion_date": "2029-07-01", "has_results": false, "last_update_posted_date": "2026-02-18", "last_synced_at": "2026-09-02T08:44:23.944Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06754501" } ] }